Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
In this study, the investigators will evaluate the safety, pharmacokinetics and effect on
target biomarkers of coagulation, cell adhesion, and leukocyte and platelet activation of
GMI-1271, an E-selectin antagonist, in healthy volunteers.